Alterity Therapeutics Limited (ATHE)

USD 2.16

(-2.7%)

Market Cap (In USD)

19.15 Million

Revenue (In USD)

4.01 Million

Net Income (In USD)

-19.12 Million

Avg. Volume

33.02 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0-3.19
PE
-
EPS
-
Beta Value
0.684
ISIN
US02155X2053
CUSIP
02155X106
CIK
1131343
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David A. Stamler M.D.
Employee Count
-
Website
https://alteritytherapeutics.com
Ipo Date
2003-09-29
Details
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.